
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Copper
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Recipient : Hospital Israelita Albert Einstein
Deal Size : Inapplicable
Deal Type : Inapplicable
COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis
Details : Copper is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Dermatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : Copper
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Recipient : Hospital Israelita Albert Einstein
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dialkylcarbamoylchloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Recipient : Abigo Medical AB
Deal Size : Undisclosed
Deal Type : Acquisition
Essity Acquires 75% of the Medical Solutions Company ABIGO Medical AB
Details : ABIGO Medical has leading innovations in advanced wound care that reduce the spread of bacteria without increasing resistance to antibiotics.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 27, 2020
Lead Product(s) : Dialkylcarbamoylchloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Recipient : Abigo Medical AB
Deal Size : Undisclosed
Deal Type : Acquisition
